Robin Kindig
Internal Medicine · la Grange, KYNPI 1235270448
Payments from drug & device makers
Across 203 payments — averaging $13.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$756
- AstraZeneca$447
- Lilly USA, LLC$336
- AbbVie$306
- GSK$203
- Amgen$105
- plus $577 from 17 others
What the payments were for
- Food & beverage$2,730100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $756 |
| AstraZeneca | 28 | $447 |
| Lilly USA, LLC | 24 | $336 |
| AbbVie(2 entities) | 23 | $306 |
| GSK | 14 | $203 |
| Amgen | 7 | $105 |
| Boehringer Ingelheim | 5 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Amarin Pharma, Inc. | 4 | $55 |
| Merck | 4 | $54 |
| Johnson & Johnson | 4 | $53 |
| Novartis | 4 | $47 |
| Eisai Inc. | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Pfizer | 2 | $25 |
| Philips North America LLC | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$2,730 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 19 | $33,503 |
| EliquisApixaban | 32 | $30,898 |
| MounjaroTirzepatide | 17 | $28,498 |
| Jentadueto XrLinagliptin/Metformin Hcl | 21 | $11,104 |
| Repatha SureclickEvolocumab | 15 | $10,413 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,608 |
| VascepaIcosapent Ethyl | 13 | $4,774 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $1,190 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $997 |
| Potassium Chloride | 24 | $835 |
| Memantine Hcl | 16 | $654 |
| Duloxetine Hcl | 24 | $631 |
| Pantoprazole Sodium | 47 | $621 |
| Rosuvastatin Calcium | 67 | $585 |
| Bumetanide | 15 | $541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $105 | $33,50319 claims |
| PfizerEliquis | $25 | $30,89832 claims |
| Lilly USA, LLCMounjaro | $336 | $28,49817 claims |
| Boehringer IngelheimJentadueto Xr | $67 | $11,10421 claims |
| GSKAnoro Ellipta | $203 | $5,60812 claims |
| AbbVieSynthroid | $306 | $13115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in la Grange
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.